Shelley Bausch
appointed Shelley Bausch to serve as a Class II director of the Company starting as of July 1, 2026
Highest-materiality recent filing
Innospec Q1 revenue $453.2M (+3% YoY); adjusted EPS $1.05 vs $1.42; dividend raised 10% to $0.92
GAAP EPS $1.22, net income $30.4M; adjusted non-GAAP EPS $1.05 (both down YoY).
Innospec reports Q4 GAAP EPS $1.91, adjusted EPS $1.50; revenue $455.6M
Net income $47.4M ($1.91 diluted) vs net loss $70.4M ($2.80 loss) last year, which included UK pension buyout.
Innospec Q3 EPS $0.52 GAAP ($1.12 adj), down from $1.33; impairments of $42.9M; dividend +10%
Revenue $441.9M flat YoY; net income $12.9M vs $33.4M; adjusted EBITDA $44.2M vs $50.5M.
Innospec Q2 2025: Revenue $439.7M (+1% YoY); GAAP EPS $0.94, adjusted EPS $1.26, net cash $266.6M
Q2 revenue $439.7M (+1% YoY); GAAP net income $23.5M ($0.94 EPS) vs $31.2M ($1.24 EPS) last year.
Innospec Q1 revenue $440.8M (-12% YoY); GAAP EPS $1.31, adj EPS $1.42; dividend +10%
Net income $32.8M ($1.31 diluted EPS) vs $41.4M ($1.65) a year ago; adjusted EPS $1.42 vs $1.75.
Innospec Q4 GAAP loss $2.80 on $155.6M pension charge; adjusted EPS $1.41
GAAP net loss of $70.4M ($2.80 per share) driven by $155.6M non-cash UK pension buyout settlement charge.
Innospec Q3 revenue $443M (-4% YoY), EPS $1.33, dividend raised 10% to $1.55 annual
Revenue $443.4M, down 4% YoY from $464.1M; net income $33.4M vs $39.2M; GAAP EPS $1.33, adjusted $1.35.
Innospec Q2: rev $435M (-9% YoY), GAAP EPS $1.24, adj EPS $1.39, net cash $240M
Q2 revenue $435M (-9% YoY); net income $31.2M ($1.24 diluted EPS) vs $28.9M ($1.16) prior year.
Innospec Q1 revenue $500.2M (-2%); GAAP EPS $1.65, adjusted $1.75; dividend up 10%
GAAP EPS $1.65 vs $1.33; adjusted non-GAAP EPS $1.75 vs $1.38; net income $41.4M vs $33.2M.
Innospec Q4 net income up 48% to $37.8M; adjusted EPS $1.84 beats prior year $1.20
Revenue $494.7M (-3% YoY); net income $37.8M ($1.51 diluted) vs $25.5M ($1.02) last year.
Innospec completes acquisition of Brazilian specialty chemicals company QGP Química Geral
Acquired QGP, a Brazilian specialty chemicals firm with 300 employees, for undisclosed terms.
Innospec Q3 revenue down 10% to $464.1M; EPS $1.57; annual dividend increased 10%
Revenue $464.1M vs $513.0M last year, down 10%; net income $39.2M ($1.57 diluted EPS).
Innospec Q2 revenue up 3% to $480.4M; net income falls to $28.9M on $8M Brazil exit charge
GAAP EPS $1.16 vs $1.29 a year ago; adjusted non-GAAP EPS $1.28 vs $1.58.
Innospec reports Q1 revenue up 8% to $509.6M; GAAP EPS $1.33, adjusted EPS $1.38
Revenue $509.6M (+8% YoY) driven by strong Oilfield Services growth.
Innospec Q4 revenue up 24% to $510.7M; adjusted EPS $1.20 vs $1.30 YoY; net cash $147.1M
Q4 revenue $510.7M (+24% YoY); net income $25.5M ($1.02 diluted EPS) vs $23.9M ($0.96) last year.
Innospec Q3 revenue up 36% to $513M; adjusted EPS $1.74 vs $1.15; dividend raised 10%
Revenue $513.0M, +36% YoY; net income $38.7M ($1.55 EPS) vs $23.4M ($0.94).
Innospec Q2 2022 revenue up 32% to $467.6M; adjusted EPS $1.58 vs $1.30 last year
GAAP EPS of $1.29 ($32.3M net income) versus $0.90 in Q2 2021.
Innospec Q1 revenue up 39% to $472.4M; adjusted EPS $1.53; dividend increased 11%
Revenue $472.4M (+39% YoY); net income $36.5M ($1.46 diluted EPS) vs $23.4M ($0.94)
Innospec Q4 revenues up 33% to $413M; GAAP EPS $0.96, adjusted EPS $1.30; announces $50M buyback
Q4 revenues $413.2M (+33% YoY); GAAP diluted EPS $0.96, adjusted non-GAAP EPS $1.30.
Innospec Q3 revenue up 42% to $376.1M; adj. EPS $1.15; annual dividend raised 12% to $1.16
Revenue $376.1M (+42% YoY); net income $23.4M ($0.94 GAAP EPS) vs $12.7M ($0.51) last year.
Innospec Q2 revenue up 45% to $354.5M; adjusted EPS $1.30 vs loss year ago
Revenue $354.5M (+45% YoY); net income $22.4M ($0.90 EPS) vs loss of $39.7M a year ago.
appointed Shelley Bausch to serve as a Class II director of the Company starting as of July 1, 2026
On March 31, 2024, Dr. Philip Boon, Executive Vice President and Chief Operating Officer of Innospec Inc. (the “Company”), informed the Company of his decision to officially retire effective March 31, 2025.
On May 8, 2023, Robert Paller, a member of the Board of Directors (the “Board”) of Innospec Inc. (the “Company”), informed the Company of his decision not to stand for re-election to the Board when his current term as a director expires at the Company’s 2024 Annual Meeting of Stockholders (“Annual Meeting”).
appointed Mr. Leslie J. Parrette to serve as a Class II director of the Company until the 2022 annual meeting of stockholders of the Company.
Max materiality 0.75 · Median 0.65 · Most common event earnings